Lartruvo (olaratumab) - New Clinical Trial Information Important To Prescribing Decisions

LARTRUVO (olaratumab) Recall Summary A clinical trial found that LARTRUVO, a cancer drug, did not improve survival when combined with standard chemotherapy in certain soft tissue sarcoma patients. Health Canada is notifying healthcare providers across the country about this new trial information so they can make informed prescribing decisions for their patients.

Reason

Product safety

Category

drug recall

Country

Canada

Agency

HC-DRUGS

Recall date

2019-01-30

Status

Ongoing

Distribution

Canada-wide

Official recall notice from HC-DRUGS

Recall details on Nibble Recalls: https://trynibble.app/recalls/1c381d88-d2d9-404e-9fc8-88b0fd59223e